Fat Loss + GLP-1sClinical / investigationalEarly humanUpdated 2026-04-24

Peptide reference file

Ecnoglutide

Trending #30 in Fat2.1k searches/moMixed

Ecnoglutide is an investigational GLP-1 receptor agonist in the obesity and metabolic-disease pipeline.

Current readout: early human evidence, clinical / investigational status, investigational approval state, human evidence appears in the current trail, registered trials are linked, and 4 linked sources in the seed trail.

PubChem CID 162625103 | 9 PubMed results | 11 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

Ecnoglutide is mostly discussed because it shows up in the broader race to build new GLP-1 or incretin medicines beyond the current leaders.

The public claim is straightforward: It shows up in the broader race to build new GLP-1 or incretin medicines beyond the current leaders. Early human metabolic evidence without approval status.

In plain language, ecnoglutide is an investigational GLP-1 receptor agonist in the obesity and metabolic-disease pipeline.

Early humanClinical / investigational
GLP-1 receptorAppetite signalingWeight loss

Aliases: XW003

SpecimenEcnoglutide specimen
CCCCHHHHHHHNO
Formula
C194H304N48O61
Mass
4285
Evidence
Early human
Elements
4

Most commonly discussed in relation to GLP-1 receptor, Appetite signaling, Weight loss.

What Ecnoglutide is

Ecnoglutide is an investigational GLP-1 receptor agonist in the obesity and metabolic-disease pipeline.

Ecnoglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it shows up in the broader race to build new GLP-1 or incretin medicines beyond the current leaders.

The useful starting point is to separate the molecule itself from the internet story around it. It shows up in the broader race to build new GLP-1 or incretin medicines beyond the current leaders.

Why people keep looking it up

It shows up in the broader race to build new GLP-1 or incretin medicines beyond the current leaders.

Ecnoglutide is an investigational GLP-1 receptor agonist in the obesity and metabolic-disease pipeline.

Ecnoglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, appetite signaling, and weight loss. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Early human metabolic evidence without approval status.

Human data exists, but this remains clinical-stage rather than a settled approved therapy.

Mechanistic support follows established GLP-1 pharmacology.

Why this page carries the current tier: Early human metabolic evidence without approval status.

The current seed trail for Ecnoglutide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

GLP-1 development candidates should be discussed with the same caution as other investigational drugs.

Ecnoglutide remains investigational in the current record.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Ecnoglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Ecnoglutide is CID 162625103. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
162625103
Formula
C194H304N48O61
Molecular weight
4285
InChIKey
DJMLKAVQDZZBNC-NYHUXPQOSA-N

Matched synonyms include Ecnoglutide, 2459531-73-6, Ecnoglutide [INN], UNII-KM6YM7L8LH, KM6YM7L8LH, GTPL13970, GLXC-26838, XW003.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Ecnoglutide returns 11 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Ecnoglutide returns 9 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.